Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Pulmonology
•
Pulmonary Vascular Disease
Do you use anticoagulants in the management of patients with pulmonary veno-occlusive disease (PVOD)?
Related Questions
How would you manage symptomatic, bilateral subsegmental PE developed after long air travel?
How do you risk stratify patients with different WHO groups of pulmonary hypertension prior to non-cardiac surgeries?
How would you approach a pulmonary-renal PR3+ ANCA vasculitis patient who has persistent re-narrowing of mainstem bronchus after several dilatation and stenting procedures, with other anca features well-controlled on rituximab & avacopan?
In cases of intermediate-risk pulmonary embolism, what factors influence your decision to pursue catheter-directed thrombolysis?
How do you follow pulmonary embolism patients who have completed anticoagulation?
When do you consider the use of PH specific therapies in patients with pre-capillary pulmonary hypertension associated with sickle cell disease?
How do you manage concurrent nonlife-threatening hemoptysis and acute pulmonary embolism?
Have you noticed poor response to Tyvaso DPI compared to the nebulized form in PH-ILD?
Do you obtain an echocardiogram as a part of risk stratification in all patients hospitalized with an acute pulmonary embolism?
How long post operatively do you wait before transitioning from parenteral anticoagulation to oral anticoagulants after pulmonary thromboendarterectomy for CTEPH?
